Download PDF
Thromb Haemost 1984; 52(03): 329-332
DOI: 10.1055/s-0038-1661207
Original Article
Schattauer GmbH Stuttgart

Gabexate Mesilate (Foy®) as an Anticoagulant in Extracorporeal Circulation in Dogs and Sheep

B Oedekoven
The Department of Physiology RWTH Aachen, Aachen, FRG
,
R Bey
The Department of Physiology RWTH Aachen, Aachen, FRG
,
K Mottaghy
The Department of Physiology RWTH Aachen, Aachen, FRG
,
H Schmid-Schönbein
The Department of Physiology RWTH Aachen, Aachen, FRG
› Author Affiliations
Further Information

Publication History

Received 19 July 1984

Accepted 25 September 1984

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Gabexate mesilate (GM), a synthetic serine protease inhibitor with a short half-life time of approx. 80 sec, was applied as the exclusive anticoagulant in small scale extracorporeal circulation in narcotized dogs and sheep. The animals underwent a veno-venous bypass. As the blood was drawn out of the femoral vein, GM was infused immediately into the extracorporeal system. GM was greatly reduced because of its short half-life time before the blood reentered the animal via a brachial vein. In order to control the coagulatory state of the blood, the Activated Clotting Time (ACT), Partial Thromboplastine Time (PTT) and Recalcification Time (RT) were measured in regular intervals. In addition, a screen pressure test device was used to monitor on line during ECC the tendency of blood clotting. It was shown that the blood of the extracorporeal system was sufficiently anticoagulated by an infusion of 0.03 mg/ml/min GM. During two hours ECC, simultaneously measured ACT - values of the animals only differed up to 10 percent from the native values. Pilot studies have shown that the results of these model investigations could be successfully transferred to extracorporeal circulation with membrane oxygenators and pumps as they are clinically used.

Key words

Gabexate mesilate - Extracorporeal circulation - Screen pressure
 

  • References

  • 1 Saitoh Y. Review of clinical results with gabexate mesilate (FOY) in Japan. In: Proteinasen-Inhibition, FOY-Workshop Düsseldorf 1981. Grözinger K-H, Schrey A, Wabnitz RW. (Eds) Universitätsdruckerei und Verlag Dr. C Wolf & Sohn; München FRG: 1982. pp 108-122
    Search in Google Scholar
  • 2 Ohno H, Kambayashi J, Chang SW, Kosaki G. FOY: [Ethyl-p-(6- guanidino-hexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. II. In vivo effect on coagulo-fibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1981; 24: 445-452
    CrossrefPubMedSearch in Google Scholar
  • 3 Stemberger A, Stöhr R, Asherl R, Wendt P, Haas S, Blümel G. Einfluß von FOY auf die Proteolyse-Meachnismen von Gerinnung und Fibrinolyse. In: Proteasen-Inhibition, FOY-Workshop Düsseldorf 1981. Grözinger K-H, Schrey A, Wabnitz RW. (Eds) Universitätsdruckerei und Verlag Dr. C. Wolf & Sohn; München FRG: 1982. pp 203-214
    Search in Google Scholar
  • 4 Noack E. Pharmakologische Grundlagen zur therapeutischen Anwendbarkeit von Gabexat Mesilat (FOY). In: Proteasen-Inhibition, FOY-Workshop Düsseldorf 1981. Grözinger K-H, Schrey A, Wabnitz RW. (Eds) Universitätsdruckerei und Verlag Dr. C Wolf & Sohn; München FRG: 1982. pp 44-56
    Search in Google Scholar
  • 5 Bruhn HD. Niedrig dosiertes Heparin (low dose heparin) Wirkungsweise und Indikationen. Schattauer; Stuttgart - New York: 1980. 2 36-39
    Search in Google Scholar
  • 6 Kakkar VV. Antithrombin-III - ein wichtiger Parameter in der klinischen Chemie. Diagnostica Dialog. Boehringer Mannheim GmbH; 1981. 1 1-3
    Search in Google Scholar
  • 7 Bey R, Mottaghy K, Oedekoven B, Schmid-Schönbein H. Reduction of heparin in extracorporeal circulations (ECC) in small animals applying different protacyclin. Proceedings Europ Soc Artif Organs. Belenger J. (Ed) Saunders Company; London: 1982. 9 153-156
    Search in Google Scholar
  • 8 Eika C, Godal HC. Thrombocytopenia in rabbits induced by heparin, protamine and polybrene. Scand J Haematol 1971; 8: 481-486
    PubMedSearch in Google Scholar
  • 9 Godal HC. Thrombocytopenia and heparin. Thromb Haemostas 1980; 43: 222-224
    PubMedSearch in Google Scholar
  • 10 Bruhn HD. Niedrig dosiertes Heparin (low dose heparin) Wirkungsweise und Indikationen. Schattauer; Stuttgart - New York: 1980. 2 36-39
    Search in Google Scholar
  • 11 Jack A. Use of activated clotting time to monitor heparin during cardiac surgery. Ann Thorac Surg 1979; 28: 69-72
    CrossrefPubMedSearch in Google Scholar
  • 12 Swank RL, Roth JG, Jansen J. Screen filtration pressure method and adhesiveness and aggregation of blood cells. J Appl Physiol 1964; 19: 340-346
    CrossrefPubMedSearch in Google Scholar
  • 13 Swank RL. Alteration of blood on storage: measurement of adhesiveness of “aging” platelets and leucocytes and their removal by filtration. N Engl J Med 1961; 265: 728-733
    CrossrefPubMedSearch in Google Scholar
  • 14 Swank RL, Hirsch H, Isselhard W. Continuous filtration of blood through pyrex glass wool filters. 2nd Europ Conf Microcirculation, Pavia 1962 Bibl Anat 1964; 4: 62-71
    PubMedSearch in Google Scholar
  • 15 Lester A, Mottaghy K, Mussler K. Ein Monitoring-System zur Anzeige und Überwachung von Vitalparametem und anderen Meßwerten während extrakorporaler Zirkulation. Biomed Technik 1983; 28: 29
    CrossrefPubMedSearch in Google Scholar